Table 3.

Rate of Incident TB in entire cohort and subgroup analysis

Characteristics	Entire Cohort (n = 1904)		Patients with NO baseline prevalent TB (n = 1267)
	Number of patients (n)	Incidence rate (95% CI)per 100 person years	Number of patients (n)	Incidence rate (95% CI) per 100 person years
Total patients	182	1.85 (1.604, 2.144)	113	1.73 (1.436, 2.076)
Age (years)
≤ 40 years	100	1.83 (1.502, 2.223)	63	1.75 (1.363, 2.233)
> 40 years	82	1.89 (1.521, 2.344)	50	1.71 (1.292, 2.249)
Gender
Female	50	1.49 (1.132, 1.971)	35	1.34 (0.961, 1.865)
Male	132	2.04 (1.721, 2.421)	78	1.98 (1.589, 2.478)
History of prior TB at baseline
Yes	69	2.11 (1.666, 2.671)
No	113	1.73 (1.436, 2.076)
Haemoglobin at baseline (g/dl)	(n = 156)		(n = 88)
≤ 10	53	2.84 (2.171, 3.719)	65	2.79 (1.853, 4.196)
> 10	103	1.58 (1.304, 1.919)	23	1.43 (1.125, 1.830)
Virologic status on ART
Virologic failure (VF)	105	8.51 (7.030, 10.307)	71	10.23 (8.107, 12.910)
Virologic suppression (VS)	77	0.90 (0.717, 1.122)	42	0.72 (0.530, 0.972)
IPT
ART plus IPT	5	0.20 (0.081, 0.469)	2	0.11 (0.026, 0.423)
ART alone	177	2.44 (2.106, 2.828)	111	2.38 (1.979, 2.872)
Duration of ART (months)
≤ 12	33	24.32 (17.293, 34.215)	23	25.58 (16.998, 38.492)
13–36	52	5.46 (4.162, 7.167)	29	4.32 (3.005, 6.223)
37–60	44	2.54 (1.890, 3.413)	28	2.41 (1.666, 3.495)
> 60	53	0.75 (0.579, 0.992)	33	0.72 (0.507, 1.004)
Pre ART CD4 count (cells/mm3)
≤ 50	32	2.28 (1.612, 3.224)	18	2.57 (1.621, 4.085)
51–200	108	2.20 (1.824, 2.660)	59	1.98 (1.537, 2.560)
201–500	41	1.28 (0.943, 1.740)	35	1.35 (0.967, 1.875)
>  500	1	0.32 (0.045, 2.303)	1	0.36 (0.052, 2.625)
Current/ updated CD4 count (cells/mm3)
≤ 200	107	7.36 (6.090, 8.896)	65	8.35 (6.548, 10.648)
201–350	36	1.75 (1.265, 2.432)	22	1.64 (1.078, 2.486)
351–500	20	1.03 (0.667, 1.602)	12	0.97 (0.552, 1.711)
>  500	19	0.43 (0.277, 0.681)	14	0.44 (0.260, 0.741)

ART antiretroviral therapy, IPT Isoniazid preventive therapy, TB tuberculosis